Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,217,814
  • Shares Outstanding, K 131,560
  • Annual Sales, $ 80,370 K
  • Annual Income, $ -115,380 K
  • 60-Month Beta 1.05
  • Price/Sales 50.40
  • Price/Cash Flow N/A
  • Price/Book 5.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.56
  • Number of Estimates 1
  • High Estimate -0.56
  • Low Estimate -0.56
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.78 +5.10%
on 08/10/20
35.73 -9.46%
on 07/20/20
-0.08 (-0.25%)
since 07/10/20
3-Month
28.64 +12.95%
on 06/11/20
35.73 -9.46%
on 07/20/20
+0.77 (+2.44%)
since 05/12/20
52-Week
18.21 +77.65%
on 03/19/20
37.96 -14.78%
on 01/10/20
+2.28 (+7.58%)
since 08/12/19

Most Recent Stories

More News
MorphoSys Reports Second Quarter and First Half 2020 Results

NVS : 84.90 (+3.00%)
XNCR : 32.49 (+1.53%)
MOR : 32.29 (+0.72%)
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi

Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.

INCY : 94.18 (+1.29%)
LLY : 152.72 (+1.39%)
NVS : 84.90 (+3.00%)
MOR : 32.29 (+0.72%)
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need - FDA granted Monjuvi Fast Track, Breakthrough Therapy and Priority...

MOR : 32.29 (+0.72%)
MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

PLANEGG & MUNICH, GERMANY / ACCESSWIRE / July 31, 2020 / MorphoSys AG (FSE:MOR)(Prime Standard Segment; MDAX & TecDAX)(NASDAQ:MOR) today announces that the U.S. Food and Drug Administration (FDA) has approved...

MOR : 32.29 (+0.72%)
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

--- FDA granted Monjuvi Fast Track, Breakthrough Therapy and Priority Review designations

MOR : 32.29 (+0.72%)
INCY : 94.18 (+1.29%)
Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

MOR : 32.29 (+0.72%)
MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) that its licensee Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) approval...

MOR : 32.29 (+0.72%)
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

VRTX : 270.93 (+3.46%)
GILD : 68.90 (+1.17%)
EBS : 129.35 (+5.74%)
MOR : 32.29 (+0.72%)
MorphoSys to Present at Upcoming Virtual Investor Conferences

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 2, 2020 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will present at the following virtual conferences:

MOR : 32.29 (+0.72%)
MorphoSys AG Reports Outcome of Annual General Meeting 2020

MOR : 32.29 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 33.05
1st Resistance Point 32.55
Last Price 32.29
1st Support Level 31.74
2nd Support Level 31.43

See More

52-Week High 37.96
Last Price 32.29
Fibonacci 61.8% 30.42
Fibonacci 50% 28.09
Fibonacci 38.2% 25.75
52-Week Low 18.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar